TransCode Therapeutics (RNAZ) Competitors $10.65 -0.46 (-4.14%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$11.25 +0.60 (+5.63%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNAZ vs. CLSD, MRSN, LVTX, KPTI, XLO, AKTX, MAAQ, SNYR, RANI, and DYAIShould you be buying TransCode Therapeutics stock or one of its competitors? The main competitors of TransCode Therapeutics include Clearside Biomedical (CLSD), Mersana Therapeutics (MRSN), LAVA Therapeutics (LVTX), Karyopharm Therapeutics (KPTI), Xilio Therapeutics (XLO), Akari Therapeutics (AKTX), Mana Capital Acquisition (MAAQ), Synergy CHC (SNYR), Rani Therapeutics (RANI), and Dyadic International (DYAI). These companies are all part of the "pharmaceutical products" industry. TransCode Therapeutics vs. Its Competitors Clearside Biomedical Mersana Therapeutics LAVA Therapeutics Karyopharm Therapeutics Xilio Therapeutics Akari Therapeutics Mana Capital Acquisition Synergy CHC Rani Therapeutics Dyadic International TransCode Therapeutics (NASDAQ:RNAZ) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk. Does the media favor RNAZ or CLSD? In the previous week, TransCode Therapeutics' average media sentiment score of 0.00 equaled Clearside Biomedical'saverage media sentiment score. Company Overall Sentiment TransCode Therapeutics Neutral Clearside Biomedical Neutral Which has stronger earnings and valuation, RNAZ or CLSD? TransCode Therapeutics has higher earnings, but lower revenue than Clearside Biomedical. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTransCode TherapeuticsN/AN/A-$16.75MN/AN/AClearside Biomedical$1.66M18.12-$34.35M-$0.41-0.93 Which has more risk and volatility, RNAZ or CLSD? TransCode Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of 2.08, indicating that its share price is 108% more volatile than the S&P 500. Do institutionals and insiders hold more shares of RNAZ or CLSD? 18.8% of Clearside Biomedical shares are owned by institutional investors. 0.0% of TransCode Therapeutics shares are owned by insiders. Comparatively, 6.2% of Clearside Biomedical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate RNAZ or CLSD? TransCode Therapeutics presently has a consensus price target of $280.00, suggesting a potential upside of 2,529.11%. Clearside Biomedical has a consensus price target of $4.20, suggesting a potential upside of 996.32%. Given TransCode Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe TransCode Therapeutics is more favorable than Clearside Biomedical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Clearside Biomedical 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17 Is RNAZ or CLSD more profitable? TransCode Therapeutics has a net margin of 0.00% compared to Clearside Biomedical's net margin of -818.57%. Clearside Biomedical's return on equity of 0.00% beat TransCode Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TransCode TherapeuticsN/A -578.88% -222.61% Clearside Biomedical -818.57%N/A -114.23% SummaryClearside Biomedical beats TransCode Therapeutics on 6 of the 10 factors compared between the two stocks. Get TransCode Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNAZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAZ vs. The Competition Export to ExcelMetricTransCode TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.26M$2.51B$5.48B$9.57BDividend YieldN/A1.78%3.99%4.17%P/E RatioN/A19.6629.9425.14Price / SalesN/A425.10398.9486.71Price / CashN/A165.0335.9458.58Price / Book-0.194.198.105.59Net Income-$16.75M$31.61M$3.26B$265.48M7 Day Performance-7.39%0.95%0.68%1.22%1 Month Performance15.14%2.90%2.46%0.39%1 Year Performance-99.86%4.11%27.69%23.47% TransCode Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAZTransCode Therapeutics1.9611 of 5 stars$10.65-4.1%$280.00+2,529.1%-99.9%$9.26MN/A0.009Upcoming EarningsCLSDClearside Biomedical2.3984 of 5 stars$0.45-10.5%$4.20+843.6%-62.8%$38.64M$1.66M-1.0930Upcoming EarningsMRSNMersana Therapeutics3.8963 of 5 stars$6.83-11.3%$130.00+1,803.4%-81.9%$38.39M$40.50M-11.58150Upcoming EarningsLVTXLAVA Therapeutics1.7156 of 5 stars$1.52+6.3%$3.17+108.3%-12.6%$37.62M$11.98M-1.4660News CoveragePositive NewsAnalyst DowngradeHigh Trading VolumeKPTIKaryopharm Therapeutics3.4501 of 5 stars$4.37+0.5%$37.40+755.8%-67.4%$37.58M$145.24M-0.33380XLOXilio Therapeutics3.4656 of 5 stars$0.68-2.1%$4.00+486.5%-23.8%$36.08M$6.34M-0.8170News CoverageUpcoming EarningsAnalyst ForecastAnalyst RevisionAKTXAkari Therapeutics3.2678 of 5 stars$1.14+1.3%$5.00+340.5%-72.1%$36.04MN/A0.009High Trading VolumeMAAQMana Capital AcquisitionN/A$4.39-4.2%N/A+864.0%$35.65MN/A0.001SNYRSynergy CHC3.9981 of 5 stars$3.72-1.8%$10.00+168.8%N/A$34.85M$34.83M0.0040RANIRani Therapeutics1.8951 of 5 stars$0.55+3.6%$7.33+1,231.2%-78.1%$33.63M$1.03M-0.56110Negative NewsEarnings ReportShort Interest ↑DYAIDyadic International3.2989 of 5 stars$1.11+0.9%$6.00+440.5%-29.6%$33.10M$3.49M-5.557Upcoming Earnings Related Companies and Tools Related Companies Clearside Biomedical Competitors Mersana Therapeutics Competitors LAVA Therapeutics Competitors Karyopharm Therapeutics Competitors Xilio Therapeutics Competitors Akari Therapeutics Competitors Mana Capital Acquisition Competitors Synergy CHC Competitors Rani Therapeutics Competitors Dyadic International Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNAZ) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNAZ Stock Alerts